P-80 Analysis of plasma angiogenesis factors on the efficacy of FOLFIRI plus ramucirumab and FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer from WJOG9216G randomized phase II study

• DOI: 10.1016/j.annonc.2023.04.136
• Publication Date: 2023-07-01T14:55:17Z
• Authors: T. Yamada; Y. Kito; K. Sakai; K. Nishio; K. Yamazaki; H. Shoji; T. Tsushima; S. Mitani; K. Shiraishi; H. Yasui; H. Hara; K. Shimozaki; T. Esaki; H. Shimokawa; T. Tsuzuki; S. Kajiura; T. Masuishi; E. Baba; K. Yoshimura; H. Kawakami; S. Hironaka; K. Muro
• Keywords: Ramucirumab; FOLFIRI